# Lantern Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lantern-pharma

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.lanternpharma.com
- Total disclosed funding: $4.7M
- Latest round: Series A (May 2, 2017)
- Investors on record: 2

## About

Based in Texas, US, and founded in 2013 Lantern Pharma, Inc. is a biotechnology company that provides oncology therapeutics using artificial intelligence, genomics, and machine learning to identify and developed cancer therapies. The company becomes a publicly listed company on the NASDAQ stock exchange, In June 2020. The company has approximately 18 employees.

Lantern Pharma, Inc. is a biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.

The company generates revenue by offering the developed therapies to pharmaceutical companies.

The company’s long-term objective is to identify more oncology-specific preclinical points towards the development of the RADR platform.

## Funding rounds

- Series A, May 2, 2017, $3.7M — Bios Partners, Green Park & Golf Ventures
- Seed, Feb 26, 2015, $1M — Green Park & Golf Ventures

## Investors

- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Seed, Series A
- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series A